Research Topics
Species | P F PinskySummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Estimation and prediction for cancer screening models using deconvolution and smoothingP F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Biometrics 57:389-95. 2001..This, along with the realistic preclinical incidence function described above, results in more accurate estimates of sojourn time and lead time and allows for estimation of quantities related to overdiagnosis, which we define here...
Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Int J Cancer 132:2127-33. 2013..95 (95% CI: 0.74-1.23), respectively. Having utilized ROCA in PLCO would not have led to a significant mortality benefit of screening. However, ROCA could still show a significant effect in other screening trials, including UKCTOCS...
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Cancer 119:593-601. 2013..The authors attempted to estimate the effect of these drugs on prostate cancer mortality to be able to better evaluate the cost-benefit tradeoff...
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
Cancer Epidemiol 36:e401-6. 2012..The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized screening trial demonstrated no mortality effect of screening. Here we analyze prostate cancer specific survival in PLCO and its relation to screening...
Enriched designs for assessing discriminatory performance--analysis of bias and variancePaul F Pinsky
Division of Imaging and Applied Mathematics, Office of Science and Engineering Laboratories, Center for Devices and Radiologic Health, Food and Drug Administration, Silver Spring, MD, USA
Stat Med 31:501-15. 2012..These principles are illustrated with a simulation study motivated by the Digital Mammographic Imaging Screening Trial study, a trial of digital versus screen film mammography...
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethedsa, Maryland, USA
Urology 68:352-6. 2006..Here we examine the relationship between prostate volume and PSA level in a large, geographically diverse sample of men undergoing prostate cancer screening...
Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States)Paul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Causes Control 17:1017-24. 2006..Lung cancer rates vary considerably among U.S. racial/ethnic groups. We quantitatively analyzed the extent to which these differences can be attributed to differential patterns of smoking...
Abnormalities on chest radiograph reported in subjects in a cancer screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Chest 130:688-93. 2006..There is little literature either on the prevalence in the general population of various abnormalities seen on CXRs or on the risks associated with these abnormalities...
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
BJU Int 99:775-9. 2007..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
Prostate-specific antigen velocity and prostate cancer gleason grade and stagePaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer 109:1689-95. 2007..The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial...
Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
J Natl Med Assoc 100:291-8. 2008..Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial...
The yield of surveillance colonoscopy by adenoma history and time to examinationPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Clin Gastroenterol Hepatol 7:86-92. 2009..Surveillance colonoscopy is recommended for subjects with a history of adenomas but there is limited information on the yield of surveillance...
Estimating rates of true high-grade disease in the prostate cancer prevention trialPaul Pinsky
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, EPN 3064, Bethesda, MD 20892, USA
Cancer Prev Res (Phila) 1:182-6. 2008..Results from RP show that misclassification rates on biopsy were higher in the placebo arm and that the rate of true high-grade disease may have been lower in the finasteride arm...
One year recurrence of aberrant crypt fociPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Prev Res (Phila) 3:839-43. 2010..After removal of ACF at baseline, ACF counts 1 year later were only slightly reduced and were significantly correlated with the baseline ACF count. The results of this study do not support a role for ACF in clinical practice...
Variability in flexible sigmoidoscopy performance among examiners in a screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Clin Gastroenterol Hepatol 3:792-7. 2005..In 2 European trials, wide variability across examiners in FSG performance was noted. We report on the performance of examiners in the US randomized trial: the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial...
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screenPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer 103:157-63. 2005....
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trialP F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Am J Epidemiol 165:874-81. 2007..Standardized incidence ratios for all cancer were 84 in women and 73 in men, with a large range of standardized incidence ratios observed for specific cancers...
GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenomaLee E Moore
National Cancer Institute, 6120 Executive Boulevard, EPS 7034, Bethesda, MD 20892 7240, USA
Cancer Epidemiol Biomarkers Prev 14:1823-7. 2005..These findings only became apparent using a newly developed assay able to distinguish heterozygous from wild-type individuals. Our data provide evidence that phenotypic differences between these two groups exist...
Methods for etiologic and early marker investigations in the PLCO trialRichard B Hayes
Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 8114, Bethesda, MD 20892, USA
Mutat Res 592:147-54. 2005..g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial...
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention TrialStuart G Baker
Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892 7354, USA
Biostatistics 11:413-8. 2010..With such an important result at stake, a transparent analysis was important...
Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma riskUlrike Peters
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, 6120 Executive Boulevard, EPS 3024, Rockville, MD 20852, USA
Cancer Epidemiol Biomarkers Prev 13:546-52. 2004..We investigated the association of circulating vitamin D metabolites and a genetic variant of the VDR gene with advanced colorectal adenoma, a precursor lesion of colorectal cancer...
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
Am J Epidemiol 157:792-9. 2003..7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios...
Results of repeat sigmoidoscopy 3 years after a negative examinationRobert E Schoen
Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
JAMA 290:41-8. 2003..The necessary frequency of endoscopic colorectal cancer screening after a negative examination is uncertain...
An early- and late-stage convolution model for disease natural historyPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, EPN 3064, Bethesda, Maryland 20892, USA
Biometrics 60:191-8. 2004..As an example, we fit the model to data from the Mayo Lung Cancer Screening trial...
Predictors of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopyPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7346, USA
Clin Gastroenterol Hepatol 1:103-10. 2003..The relationship between distal and proximal colonic findings is uncertain. Thus, there is no consensus on which findings on screening flexible sigmoidoscopy should trigger colonoscopy...
Meat, meat cooking methods and preservation, and risk for colorectal adenomaRashmi Sinha
Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
Cancer Res 65:8034-41. 2005..04; 95% CI, 0.90-1.19). Our study of screening-detected colorectal adenomas shows that red meat and meat cooked at high temperatures are associated with an increased risk of colorectal adenoma...
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancerJohn K Gohagan
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, EPN 3064, Bethesda, MD 20892, USA
Lung Cancer 47:9-15. 2005..A total of 16 stage III-IV cancers were observed in the LDCT arm versus nine in the CXR arm. The LSS has established the feasibility of a RCT comparing annual spiral CT to chest X-ray for lung cancer screening...
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 173:746-50; discussion 750-1. 2005..Followup of positive screens in PLCO is done by subject personal physicians and it is outside of trial control. We describe the pattern of prostate biopsy in men with positive screens in PLCO...
Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopyRobert E Schoen
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvani 15213 2582, USA
Gastroenterology 131:1683-9. 2006..To examine the yield at colonoscopy when a given size lesion is observed, we assessed the yield of advanced adenoma and cancer at colonoscopy based on the size of the abnormality detected at flexible sigmoidoscopy (FSG)...
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trialGerald L Andriole
Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
J Natl Cancer Inst 97:433-8. 2005..We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up...
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trialJoel L Weissfeld
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
J Natl Cancer Inst 97:989-97. 2005..Here we report findings from the baseline screening flexible sigmoidoscopy examination...
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trialE David Crawford
Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
J Urol 175:1286-90; discussion 1290. 2006..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
Results of a randomized controlled trail of prostate cancer screeningPaul F Pinsky
Prostate 61:371. 2004
Claims of sex-gene interactionsPaul F Pinsky
JAMA 298:2741-2; author reply 2742. 2007
